Phase I Clinical Trial to Evaluate the Safety and Tolerability and Pharmacokinetics of MSB0254 Injection in Patients With Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 07 Apr 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs MSB 0254 (Primary)
Indications Cholangiocarcinoma; Gastric cancer; Liver cancer; Malignant thymoma; Neuroendocrine tumours; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Sponsors MabSpace Biosciences; Transcenta Holding

31 Mar 2023 Status changed from recruiting to discontinued as per sponsor decision.
07 Jun 2022 Results (as of 10th Jan 2022; n=22) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
28 Apr 2022 According to a Transcenta Holding media release, data will be presented at the 2022 annual meeting of American Society of Clinical Oncology ("2022 ASCO Annual Meeting").

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com